TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tuberculosis in HIV-infected Patients Managed in Health Centres in Ethiopia - Identification of a Screening Algorithm for Active Tuberculosis and Determination of Outcome of Combined Antituberculosis and Antiretroviral Treatment
Brief Summary: Background: Increased access to antiretroviral therapy (ART) in Africa will require decentralization to primary health care. For this purpose, adapted methods for management of patients co-infected with tuberculosis (TB) and HIV are needed. Improved detection of TB in patients starting ART, and assessment of co-administration of ART and TB treatment are priorities in this field.

Aims: To identify clinical predictors of TB in patients starting ART, and to construct screening algorithms for TB in this population; to assess ART outcomes in patients receiving TB treatment at health centre level.

Work plan: The project is performed in health centres providing ART in Ethiopia. A cohort of HIV positive patients initiating ART is prospectively followed. Baseline characteristics are registered; blood samples for CD4 cells, HIV RNA and immunological markers are collected, as well as sputum for TB culture and PCR. During ART, clinical data, CD4 cell counts and HIV RNA levels are followed. Patients with TB are compared to those without TB with regard to ART outcome. Baseline factors associated with TB will be used to construct TB screening algorithms.

Recruitment of the cohort was completed in March 2013; follow-up for determination of long term outcome of ART will be continued until 2016.

Significance: These studies give insight into TB-HIV co-infection at primary health care level in a Sub-Saharan region, and may impact future guidelines for management of such patients.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Interventional; Type: EXPERIMENTAL; Interventions: Diagnostic Test: Xpert MTB/RIF Ultra (Ultra) | Intervention Type: DIAGNOSTIC_TEST; Name: Xpert MTB/RIF Ultra (Ultra); Assigned to Arm(s): Interventional
B: Arm Label: Antiretroviral therapy, tuberculosis; Type: N/A; Interventions: N/A
C: Arm Label: LAM plus standard care; Type: EXPERIMENTAL; Interventions: Device: Urine LAM strip test | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Urine LAM strip test; Assigned to Arm(s): LAM plus standard care
D: Arm Label: Xpert MTB/RIF; Type: EXPERIMENTAL; Interventions: Procedure: Xpert MTB/RIF assay | Arm Label: Sputum smear microscopy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Smear microscopy | Intervention Type: PROCEDURE; Name: Xpert MTB/RIF assay; Assigned to Arm(s): Xpert MTB/RIF | Intervention Type: PROCEDURE; Name: Smear microscopy; Assigned to Arm(s): Sputum smear microscopy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tuberculosis in HIV-infected Patients Managed in Health Centres in Ethiopia - Identification of a Screening Algorithm for Active Tuberculosis and Determination of Outcome of Combined Antituberculosis and Antiretroviral Treatment
Brief Summary: Background: Increased access to antiretroviral therapy (ART) in Africa will require decentralization to primary health care. For this purpose, adapted methods for management of patients co-infected with tuberculosis (TB) and HIV are needed. Improved detection of TB in patients starting ART, and assessment of co-administration of ART and TB treatment are priorities in this field.

Aims: To identify clinical predictors of TB in patients starting ART, and to construct screening algorithms for TB in this population; to assess ART outcomes in patients receiving TB treatment at health centre level.

Work plan: The project is performed in health centres providing ART in Ethiopia. A cohort of HIV positive patients initiating ART is prospectively followed. Baseline characteristics are registered; blood samples for CD4 cells, HIV RNA and immunological markers are collected, as well as sputum for TB culture and PCR. During ART, clinical data, CD4 cell counts and HIV RNA levels are followed. Patients with TB are compared to those without TB with regard to ART outcome. Baseline factors associated with TB will be used to construct TB screening algorithms.

Recruitment of the cohort was completed in March 2013; follow-up for determination of long term outcome of ART will be continued until 2016.

Significance: These studies give insight into TB-HIV co-infection at primary health care level in a Sub-Saharan region, and may impact future guidelines for management of such patients.


Options:
A: Arm Label: Antiretroviral therapy, tuberculosis; Type: N/A; Interventions: N/A
B: Arm Label: Sputum induction; Type: EXPERIMENTAL; Interventions: Procedure: Sputum induction | Arm Label: No sputum induction; Type: ACTIVE_COMPARATOR; Interventions: Procedure: standard routine expectorated sputum | Intervention Type: PROCEDURE; Name: Sputum induction; Assigned to Arm(s): Sputum induction | Intervention Type: PROCEDURE; Name: standard routine expectorated sputum; Assigned to Arm(s): No sputum induction
C: Arm Label: Xpert MTB/RIF; Type: EXPERIMENTAL; Interventions: Procedure: Xpert MTB/RIF assay | Arm Label: Sputum smear microscopy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Smear microscopy | Intervention Type: PROCEDURE; Name: Xpert MTB/RIF assay; Assigned to Arm(s): Xpert MTB/RIF | Intervention Type: PROCEDURE; Name: Smear microscopy; Assigned to Arm(s): Sputum smear microscopy
D: Arm Label: Xpert MTB/Rif; Type: EXPERIMENTAL; Interventions: Other: Xpert MTB/Rif | Arm Label: Sputum smear; Type: ACTIVE_COMPARATOR; Interventions: Other: Smear microscopy | Intervention Type: OTHER; Name: Xpert MTB/Rif; Assigned to Arm(s): Xpert MTB/Rif | Intervention Type: OTHER; Name: Smear microscopy; Assigned to Arm(s): Sputum smear

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: A Randomized, Placebo-controlled, 2x2 Factorial, Double Blind Trial of Candesartan and Metoprolol
Brief Summary: Women treated for breast cancer are at increased risk for cardiovascular disease, including heart failure. In this study, by using magnetic resonance imaging (MRI), the investigators want to assess if heart failure medications such as beta blockers and angiotensin receptor blockers can prevent cardiac dysfunction during early breast cancer therapy.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Metoprolol controlled release (CR) | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Metoprolol controlled release (CR); Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
B: Arm Label: Losartan 100mg; Type: EXPERIMENTAL; Interventions: Drug: Losartan 100mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Losartan 100mg; Assigned to Arm(s): Losartan 100mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Ramipril; Type: EXPERIMENTAL; Interventions: Drug: Ramipril | Arm Label: Spironolactone; Type: EXPERIMENTAL; Interventions: Drug: Spironolactone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): Ramipril | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): Spironolactone
D: Arm Label: Metoprolol; Type: EXPERIMENTAL; Interventions: Drug: Metoprolol | Arm Label: Placebo for Metoprolol; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Candesartan; Type: EXPERIMENTAL; Interventions: Drug: Candesartan | Arm Label: Placebo for Candesartan; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Metoprolol; Assigned to Arm(s): Metoprolol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo for Metoprolol | Intervention Type: DRUG; Name: Candesartan; Assigned to Arm(s): Candesartan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo for Candesartan

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of an Infant Feeding Support Strategy for HIV-exposed Infants 6-12 Months Old in Urban Haiti
Brief Summary: The purpose of this quasi-experimental study is to evaluate the effectiveness of an infant feeding intervention in improving growth and anemia outcomes among HIV-exposed infants 6-12 months of age.


Options:
A: Arm Label: Intervention participant; Type: EXPERIMENTAL; Interventions: Other: Counseling and nutrition supplement | Intervention Type: OTHER; Name: Counseling and nutrition supplement; Assigned to Arm(s): Intervention participant
B: Intervention Type: DIETARY_SUPPLEMENT; Name: fortified spread (RUTF); Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: maize and soy flour; Assigned to Arm(s): N/A
C: Arm Label: Burundi: T24; Type: EXPERIMENTAL; Interventions: Other: Tubaramure (Burundi) | Arm Label: Burundi: TNFP; Type: EXPERIMENTAL; Interventions: Other: Tubaramure (Burundi) | Arm Label: Burundi: T18; Type: EXPERIMENTAL; Interventions: Other: Tubaramure (Burundi) | Arm Label: Burundi: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Guatemala: PROCOMIDA; Type: EXPERIMENTAL; Interventions: Other: Procomida (Guatemala) | Arm Label: Guatemala: no family ration; Type: EXPERIMENTAL; Interventions: Other: Procomida (Guatemala) | Arm Label: Guatemala: LNS; Type: EXPERIMENTAL; Interventions: Other: Procomida (Guatemala) | Arm Label: Guatemala: Sprinkles; Type: EXPERIMENTAL; Interventions: Other: Procomida (Guatemala) | Arm Label: Guatemala: reduced family ration; Type: EXPERIMENTAL; Interventions: Other: Procomida (Guatemala) | Arm Label: Guatemala: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Tubaramure (Burundi); Assigned to Arm(s): Burundi: T18, Burundi: T24, Burundi: TNFP | Intervention Type: OTHER; Name: Procomida (Guatemala); Assigned to Arm(s): Guatemala: LNS, Guatemala: PROCOMIDA, Guatemala: Sprinkles, Guatemala: no family ration, Guatemala: reduced family ration
D: Arm Label: ST-DI; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: FSm; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Milk-containing fortified spread | Arm Label: FSs; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Soy-containing fortified spread | Arm Label: LP; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Maize-soy flour | Intervention Type: DIETARY_SUPPLEMENT; Name: Milk-containing fortified spread; Assigned to Arm(s): FSm | Intervention Type: DIETARY_SUPPLEMENT; Name: Soy-containing fortified spread; Assigned to Arm(s): FSs | Intervention Type: DIETARY_SUPPLEMENT; Name: Maize-soy flour; Assigned to Arm(s): LP

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Umbilical Cord Milking Versus Immediate Cord Clamping on Systemic Blood Flow in Premature Infants
Brief Summary: Premature babies are at risk for bleeding in their brains, which can result in developmental delays or other neurological problems such as cerebral palsy. Clamping the baby's umbilical cord immediately after birth is standard, but delaying this procedure allows more of the baby's blood to move from the placenta into the baby and prevents head bleeds. However, a delay in clamping the umbilical cord is not usually done in very premature babies, because it would delay their treatment and they could get cold. Milking the umbilical cord is another way to give premature babies more of their own blood while avoiding a delay in treatment. Umbilical cord milking has been shown to improve blood pressure, decrease the need for blood transfusions, and increase the amount of urine made in the first few days of life.


Options:
A: Arm Label: Umbilical Cord Milking; Type: EXPERIMENTAL; Interventions: Procedure: Umbilical Cord Milking | Arm Label: Immediate Cord Clamping; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Immediate Cord Clamping | Intervention Type: PROCEDURE; Name: Umbilical Cord Milking; Assigned to Arm(s): Umbilical Cord Milking | Intervention Type: PROCEDURE; Name: Immediate Cord Clamping; Assigned to Arm(s): Immediate Cord Clamping
B: Arm Label: Early umbilical cord clamping (control); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Delayed umbilical cord clamping; Type: EXPERIMENTAL; Interventions: Procedure: Delayed umbilical cord clamping | Intervention Type: PROCEDURE; Name: Delayed umbilical cord clamping; Assigned to Arm(s): Delayed umbilical cord clamping
C: Arm Label: Umbilical Cord Milking; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Umbilical Cord Milking | Arm Label: Delayed Cord Clamping; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Delayed Cord Clamping | Intervention Type: PROCEDURE; Name: Umbilical Cord Milking; Assigned to Arm(s): Umbilical Cord Milking | Intervention Type: PROCEDURE; Name: Delayed Cord Clamping; Assigned to Arm(s): Delayed Cord Clamping
D: Arm Label: Early cord clamping (ECC); Type: OTHER; Interventions: Procedure: Early (≤30 seconds) cord clamping | Arm Label: Delayed cord clamping (DCC); Type: OTHER; Interventions: Procedure: Delayed (≤180 seconds) cord clamping | Intervention Type: PROCEDURE; Name: Early (≤30 seconds) cord clamping; Assigned to Arm(s): Early cord clamping (ECC) | Intervention Type: PROCEDURE; Name: Delayed (≤180 seconds) cord clamping; Assigned to Arm(s): Delayed cord clamping (DCC)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Breast Cancer and Exercise Trial in Alberta: The BETA Trial
Brief Summary: The Breast Cancer and Exercise Trial (BETA Trial) is a randomized controlled trial aimed at understanding what dose (or volume) of exercise will best reduce the risk for breast cancer, particularly among women who are between the ages of 50-74. The primary aim is to compare the effects of a high versus moderate volume exercise intervention on specific biological intermediate endpoints for breast cancer in a group of previously inactive postmenopausal women


Options:
A: Arm Label: Exercise Referral Scheme (ERS); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ERS and/or Self-management Strategies | Arm Label: ERS + Self-management Strategies; Type: EXPERIMENTAL; Interventions: Behavioral: ERS and/or Self-management Strategies | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ERS and/or Self-management Strategies; Assigned to Arm(s): ERS + Self-management Strategies, Exercise Referral Scheme (ERS)
B: Arm Label: High Volume; Type: ACTIVE_COMPARATOR; Interventions: Other: High Volume | Arm Label: Moderate Volume; Type: ACTIVE_COMPARATOR; Interventions: Other: Moderate Volume | Intervention Type: OTHER; Name: Moderate Volume; Assigned to Arm(s): Moderate Volume | Intervention Type: OTHER; Name: High Volume; Assigned to Arm(s): High Volume
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: TV viewing reduction | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: No TV viewing reduction | Intervention Type: BEHAVIORAL; Name: No TV viewing reduction; Assigned to Arm(s): Control | Intervention Type: BEHAVIORAL; Name: TV viewing reduction; Assigned to Arm(s): 1
D: Arm Label: Physical activity treatment group; Type: EXPERIMENTAL; Interventions: Behavioral: Pedal@Work | Arm Label: Wait List Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Pedal@Work Worksite Wellness | Intervention Type: BEHAVIORAL; Name: Pedal@Work Worksite Wellness; Assigned to Arm(s): Wait List Control | Intervention Type: BEHAVIORAL; Name: Pedal@Work; Assigned to Arm(s): Physical activity treatment group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of Blood Transfusion With Intravenous Iron in Gynecologic Cancer Patients Receiving Platinum Based Chemotherapy
Brief Summary: Can intravenous iron lower the rate of blood transfusion in gynecologic cancer patients receiving platinum based chemotherapy than oral iron?


Options:
A: Arm Label: Darbepoetin alfa - Group A; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin alfa | Arm Label: Placebo- Group B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa - Group A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo- Group B
B: Arm Label: Intravenous iron; Type: EXPERIMENTAL; Interventions: Drug: Intravenous iron | Arm Label: Oral iron; Type: PLACEBO_COMPARATOR; Interventions: Drug: Intravenous iron | Intervention Type: DRUG; Name: Intravenous iron; Assigned to Arm(s): Intravenous iron, Oral iron
C: Arm Label: Darbepoetin alfa 500 mcg - Group A; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin alfa - 500mcg | Arm Label: Darbepoetin alfa 2.25 mcg/kg - Group B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa - 2.25 mcg/kg | Intervention Type: DRUG; Name: Darbepoetin alfa - 2.25 mcg/kg; Assigned to Arm(s): Darbepoetin alfa 2.25 mcg/kg - Group B | Intervention Type: DRUG; Name: Darbepoetin alfa - 500mcg; Assigned to Arm(s): Darbepoetin alfa 500 mcg - Group A
D: Arm Label: Arm A (ibrutinib, rituximab); Type: EXPERIMENTAL; Interventions: Drug: Ibrutinib, Other: Laboratory Biomarker Analysis, Other: Pharmacogenomic Study, Other: Quality-of-Life Assessment, Biological: Rituximab | Arm Label: Arm B (rituximab, fludarabine phosphate, cyclophosphamide); Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Fludarabine Phosphate, Other: Laboratory Biomarker Analysis, Other: Pharmacogenomic Study, Other: Quality-of-Life Assessment, Biological: Rituximab | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Arm B (rituximab, fludarabine phosphate, cyclophosphamide) | Intervention Type: DRUG; Name: Fludarabine Phosphate; Assigned to Arm(s): Arm B (rituximab, fludarabine phosphate, cyclophosphamide) | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): Arm A (ibrutinib, rituximab) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm A (ibrutinib, rituximab), Arm B (rituximab, fludarabine phosphate, cyclophosphamide) | Intervention Type: OTHER; Name: Pharmacogenomic Study; Assigned to Arm(s): Arm A (ibrutinib, rituximab), Arm B (rituximab, fludarabine phosphate, cyclophosphamide) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm A (ibrutinib, rituximab), Arm B (rituximab, fludarabine phosphate, cyclophosphamide) | Intervention Type: BIOLOGICAL; Name: Rituximab; Assigned to Arm(s): Arm A (ibrutinib, rituximab), Arm B (rituximab, fludarabine phosphate, cyclophosphamide)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Open-label Clinical Investigation to Evaluate the Safety and Efficacy of Glucosanol in Maintaining Body Weight Loss in Overweight and Obese Subjects
Brief Summary: To date, there is no clinical evidence on the efficacy and safety of Glucosanol in maintaining weight loss beyond the study duration of 12 weeks. The rationale for this open-label study is to assess the efficacy in preventing regain of loss body weight and safety of Glucosanol in subjects who are overweight or obese over a longer period after the initial weight loss.


Options:
A: N/A
B: Arm Label: Glucosanol; Type: ACTIVE_COMPARATOR; Interventions: Device: Glucosanol | Intervention Type: DEVICE; Name: Glucosanol; Assigned to Arm(s): Glucosanol
C: Intervention Type: DRUG; Name: glucophage XR; Assigned to Arm(s): N/A
D: Arm Label: Diet/Exercise only, then Diet/Exercise plus Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin, Behavioral: Dietary modification with caloric restriction, Behavioral: Establishment of exercise protocol | Arm Label: Diet/Exercise plus Metformin, then Diet/Exercise only; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Behavioral: Dietary modification with caloric restriction, Behavioral: Establishment of exercise protocol | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Diet/Exercise only, then Diet/Exercise plus Metformin, Diet/Exercise plus Metformin, then Diet/Exercise only | Intervention Type: BEHAVIORAL; Name: Dietary modification with caloric restriction; Assigned to Arm(s): Diet/Exercise only, then Diet/Exercise plus Metformin, Diet/Exercise plus Metformin, then Diet/Exercise only | Intervention Type: BEHAVIORAL; Name: Establishment of exercise protocol; Assigned to Arm(s): Diet/Exercise only, then Diet/Exercise plus Metformin, Diet/Exercise plus Metformin, then Diet/Exercise only

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Impact of Care Pathways on Interprofessional Teamwork: an International Cluster Randomized Controlled Trial
Brief Summary: Care pathways are complex interventions to support the interprofessional team in the redesign of their care process. This international cluster randomised trial will analyse the impact of the development and implementation of care pathways on the interprofessional teamwork.


Options:
A: Arm Label: Care pathway teams.; Type: EXPERIMENTAL; Interventions: Behavioral: Care pathway. | Arm Label: Usual care teams.; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Care pathway.; Assigned to Arm(s): Care pathway teams.
B: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Other: Interdisciplinary intervention program | Intervention Type: OTHER; Name: Interdisciplinary intervention program; Assigned to Arm(s): Experimental group
C: Arm Label: Orthogeriatric unit; Type: EXPERIMENTAL; Interventions: Procedure: geriatric work-up | Arm Label: Orthopedic care as usual; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Orthopedic care as usual | Intervention Type: PROCEDURE; Name: geriatric work-up; Assigned to Arm(s): Orthogeriatric unit | Intervention Type: PROCEDURE; Name: Orthopedic care as usual; Assigned to Arm(s): Orthopedic care as usual
D: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Subacute care group; Type: OTHER; Interventions: Other: Subacute care | Arm Label: Comprehensive care group; Type: EXPERIMENTAL; Interventions: Other: Comprehensive care | Intervention Type: OTHER; Name: Comprehensive care; Assigned to Arm(s): Comprehensive care group | Intervention Type: OTHER; Name: Subacute care; Assigned to Arm(s): Subacute care group

Answer: A